Here's Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity

Danaher (DHR) dropped 12.1% this week despite topping Q2 earnings estimates and lifting full-year EPS guidance. The selloff intensified after management disclosed that $0.07 to $0.08 of the guidance raise stems from the Masimo acquisition rather than underlying business momentum. The company also trimmed expectations for biotechnology sales growth, citing timing shifts in consumables shipments.

The 12% decline erased roughly $20 billion in market cap over what amounts to an accounting clarification and a quarterly shipment delay. Biotechnology consumables revenue typically experiences lumpiness tied to customer ordering patterns, but the fundamental demand trajectory remains intact. The company still beat the quarter and raised guidance, albeit with acquisition support doing the heavy lifting.

The Motley Fool characterized the reaction as overdone, noting that biotech shipment timing issues are generally transitory and self-correct in subsequent quarters. Danaher's core life sciences and diagnostics franchises continue to benefit from secular growth trends in biopharma production and precision medicine.